


 Cite this: *Sens. Diagn.*, 2025, 4, 895

## Detection of ferrous ions in extracellular vesicles at the single-particle level by nano-flow cytometry

 Zuzhe Kang, Chenxi Liu, JunYan Chen, Qiujin Wu, Yunyun Hu, Haonan Di and Xiaomei Yan \*

Iron, particularly redox-active ferrous ions ( $\text{Fe}^{2+}$ ), is essential for biological processes. Despite their pivotal roles, analysis of  $\text{Fe}^{2+}$  ions within individual extracellular vesicles (EVs) has been hindered by the ultralow  $\text{Fe}^{2+}$  content and substantial heterogeneity of EVs. To address this, we developed a novel approach by integrating an  $\text{Fe}^{2+}$ -specific fluorescent chemosensor (Ac-FluNox) with nano-flow cytometry (nFCM) for precise single-EV  $\text{Fe}^{2+}$  mapping. Method specificity to  $\text{Fe}^{2+}$  was validated via  $\text{Fe}^{2+}$ -loaded liposomal models at the single-particle level. Comprehensive profiling of  $\text{Fe}^{2+}$  distributions in HT-1080-derived EVs under varying ferroptotic stress conditions revealed the striking heterogeneity in  $\text{Fe}^{2+}$  loading among EVs and a strong positive correlation between EV  $\text{Fe}^{2+}$  levels and their parental cells. Notably, we identified an EV-mediated  $\text{Fe}^{2+}$  export mechanism that functionally parallels to ferroportin (FPN)-dependent iron efflux, suggesting EVs may serve as a compensatory iron-release pathway during FPN inhibition. The nFCM platform achieved superior detection sensitivity with high throughput (up to  $10^4$  particles per min), providing a powerful analytical tool for investigating EV heterogeneity and  $\text{Fe}^{2+}$ -mediated regulatory networks in iron homeostasis and ferroptosis-related pathologies.

 Received 2nd May 2025,  
 Accepted 13th August 2025

DOI: 10.1039/d5sd00060b

[rsc.li/sensors](https://rsc.li/sensors)

## Introduction

Iron, the most abundant transition metal in human physiology, serves as a pivotal redox cofactor in oxygen-dependent metabolic pathways, spanning mitochondrial respiration, hemoglobin-mediated oxygen transport, and ATP synthesis, mediated by its unique electron-shutting capacity via  $\text{Fe}^{2+}/\text{Fe}^{3+}$  interconversion.<sup>1–3</sup> Cellular ion homeostasis is precisely controlled by iron-regulatory proteins that maintain the dynamic equilibrium between  $\text{Fe}^{2+}$  and  $\text{Fe}^{3+}$ .<sup>4–6</sup> Due to the high cellular abundance of reductants such as glutathione, intracellular labile iron consists of  $\text{Fe}^{2+}$  primarily, which participates in regulating iron metabolism through binding to small molecules or proteins.<sup>7–9</sup> Therefore, elucidating  $\text{Fe}^{2+}$ -mediated regulatory mechanisms provides critical insights into metabolic homeostasis and iron-regulatory networks. Although cells have evolved sophisticated systems for the uptake, transport, utilization, storage, and export of  $\text{Fe}^{2+}$ ,<sup>10–12</sup> the intricacies of intercellular  $\text{Fe}^{2+}$  regulation remain poorly understood.<sup>13–15</sup> Extracellular vesicles (EVs), nanoscale lipid-

bilayer-delimited particles that mediate intercellular communication through selective cargo transfer,<sup>16–18</sup> have emerged as key players in iron-related bioactive substance trafficking.<sup>2,19,20</sup> The biogenesis of  $\text{Fe}^{2+}$ -containing EVs occurs through coordinated interactions between multiple organelles (including endosomes, lysosomes, and mitochondria) and cytosolic  $\text{Fe}^{2+}$  pools, enabling active loading of redox-active iron during vesicle maturation. Through this mechanism, EVs critically regulate parental cell iron homeostasis and ferroptosis propagation.<sup>13,14,21</sup> Consequently, quantification of intravesicular  $\text{Fe}^{2+}$  is indispensable for deciphering EV-mediated biological functions and their underlying regulatory networks.

Iron exhibits diverse chemical speciation and functional states within EVs, encompassing free  $\text{Fe}^{2+}$ ,  $\text{Fe}^{3+}$ , and ferritin-bound iron.<sup>2</sup> While inductively coupled plasma mass spectrometry (ICP-MS) has enabled quantification of total iron content in EVs, this approach lacks specificity for discriminating between distinct iron species.<sup>22</sup> Current methodologies, including advanced fluorescent chemosensors and commercial assay kits, require EV disruption for  $\text{Fe}^{2+}$  detection,<sup>23,24</sup> thereby providing only ensemble-averaged measurements that obscure the inherent heterogeneity of EVs. Single-EV characterization technologies, such as super-resolution fluorescence microscopy, droplet digital PCR (ddPCR), and nano-flow cytometry (nFCM), have unequivocally demonstrated the marked heterogeneity of EVs in terms of size, composition, and cargo loading.<sup>25–29</sup> Consequently,

Department of Chemical Biology, MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, Key Laboratory for Chemical Biology of Fujian Province, State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen 361005, Fujian, China.  
 E-mail: xmyan@xmu.edu.cn





**Scheme 1** Single-EV  $\text{Fe}^{2+}$  profiling via Ac-FluNox labeling coupled with nFCM detection.

single-particle-resolution analysis of  $\text{Fe}^{2+}$  within EVs represents a fundamental prerequisite for investigating the heterogeneity and regulatory mechanisms of EVs in iron metabolism. Building on these technological advances, nFCM stands out as the optimal platform for single-EV  $\text{Fe}^{2+}$  analysis, uniquely combining: (i) high-throughput detection (up to  $10^4$  particles per min) essential for capturing population heterogeneity; (ii) quantitative multiparameter measurement of size, fluorescence intensity, and concentration; and (iii) sizing accuracy comparable to cryo-TEM, which collectively enabling unprecedented resolution of  $\text{Fe}^{2+}$  distribution patterns in EV subpopulations.<sup>30,31</sup>

In this study, we developed a novel method for detecting  $\text{Fe}^{2+}$  in individual EVs by integrating the  $\text{Fe}^{2+}$ -specific fluorescent chemosensor (Ac-FluNox) with nFCM (Scheme 1).

Upon esterase activation within EVs, Ac-FluNox generated morpholinorhodol (MR) through its reaction with  $\text{Fe}^{2+}$ , exhibiting detectable green fluorescence. The specificity and reliability of this  $\text{Fe}^{2+}$  labeling approach were validated using  $\text{Fe}^{2+}$ -loaded liposomes as model systems. Leveraging this platform, we performed systematic profiling of  $\text{Fe}^{2+}$  distributions and dynamic changes in EVs derived from HT-1080 cells under various ferroptosis-inducing conditions. Significantly, our results revealed a strong correlation of  $\text{Fe}^{2+}$  levels between EVs and their parental cells, providing mechanistic insights into EV-mediated regulation of iron homeostasis during ferroptosis.

## Results and discussion

### Synthesis and performance evaluation of $\text{Fe}^{2+}$ chemosensor Ac-FluNox

As illustrated in Scheme S1, the fluorescent chemosensor Ac-FluNox was synthesized according to the previously reported procedure,<sup>32,33</sup> with the target compound characterized by  $^1\text{H}$  NMR,  $^{13}\text{C}$  NMR (Fig. S1 and S2). Leveraging N-oxide chemistry for fluorescence switching, the N-O bond in Ac-FluNox isolates the nitrogen atom from p-conjugation, yielding a fluorescence turn-off state. Subsequent esterase hydrolysis followed by  $\text{Fe}^{2+}$ -mediated deoxygenation converts Ac-FluNox to morpholinorhodol (MR), which exhibits strong green fluorescence (Fig. 1a). Owing to its inherent lipophilicity, Ac-FluNox readily traverses lipid bilayers via passive diffusion, achieving efficient loading into both



**Fig. 1** Fluorescence responses of Ac-FluNox for  $\text{Fe}^{2+}$  detection in HEPES buffer (50 mM, pH 7.4, 0.2% DMSO). (a) The mechanism of  $\text{Fe}^{2+}$ -specific fluorescence activation of Ac-FluNox via sequential esterase-catalyzed hydrolysis (generating H-FluNox) and  $\text{Fe}^{2+}$ -mediated deoxygenation to yield morpholinorhodol (MR), a green-emitting fluorophore. (b) Fluorescence emission spectra of Ac-FluNox (1.0  $\mu\text{M}$ ) upon reaction with different concentrations of  $\text{Fe}^{2+}$  (0–10  $\mu\text{M}$ ) in the presence of esterase (0.1  $\text{mg mL}^{-1}$ ). (c) Dose–response curves of Ac-FluNox (1.0  $\mu\text{M}$ ) fluorescence intensity ( $I_{\text{em}} = 535 \text{ nm}$ ) with increasing  $\text{Fe}^{2+}$  (0–16  $\mu\text{M}$ ), with or without esterase (0.1  $\text{mg mL}^{-1}$ ). (d) Time-dependent fluorescence enhancement (recorded at 5 min intervals) of Ac-FluNox (1.0  $\mu\text{M}$ ) upon addition of  $\text{Fe}^{2+}$  (10  $\mu\text{M}$ ) in the presence of esterase (0.1  $\text{mg mL}^{-1}$ ). (e) Metal selectivity test against various metal ions. The error bar represents the standard deviation (s.d.) of three replicate experiments ( $n = 3$ , mean  $\pm$  s.d.).



natural EV membranes and artificial liposomes. This dual-enzyme/metal-responsive mechanism establishes **Ac-FluNox** as a promising probe for  $\text{Fe}^{2+}$  detection in EVs *via* nFCM.

The fluorescence response of **Ac-FluNox** was systematically evaluated for  $\text{Fe}^{2+}$  sensing in HEPES buffer containing esterase (0.1 mg mL<sup>-1</sup>). Upon gradual increase of  $\text{Fe}^{2+}$  (0–10  $\mu\text{M}$ ), a 75.2-fold fluorescence enhancement in green fluorescence emission ( $\lambda_{\text{ex}} = 490 \text{ nm}$ ,  $\lambda_{\text{em}} = 535 \text{ nm}$ ) was observed at 10  $\mu\text{M}$   $\text{Fe}^{2+}$  within 60 min (Fig. 1b–d), demonstrating rapid and efficient  $\text{Fe}^{2+}$  detection, a feature that leverages the ubiquitous presence of esterase in EVs for precise intravesicular  $\text{Fe}^{2+}$  analysis.<sup>34,35</sup> Furthermore, the selectivity of **Ac-FluNox** for  $\text{Fe}^{2+}$  was investigated. As demonstrated in Fig. 1e, negligible fluorescence was observed in the presence of biologically relevant interferents, confirming the probe's specificity and stability for  $\text{Fe}^{2+}$  detection in complex biological environments. Collectively, these results rigorously validated that **Ac-FluNox** not only quantitatively detects  $\text{Fe}^{2+}$  in solutions, but also serves as a highly selective sensor for monitoring  $\text{Fe}^{2+}$  changes.

### Single-liposome $\text{Fe}^{2+}$ profiling

To validate the single-particle  $\text{Fe}^{2+}$  labeling method, we synthesized liposomes (LPs) encapsulating  $\text{Fe}^{2+}$  (0–4.0  $\mu\text{M}$ ) and esterase (0.1 mg mL<sup>-1</sup>) *via* microfluidics (Fig. 2a(i) and b). During microfluidic assembly,  $\text{Fe}^{2+}$  and esterase were successfully co-encapsulated within the liposomes' aqueous lumen, leveraging their characteristic phospholipid bilayer-enclosed aqueous core architecture (Fig. 2b). The liposomes were stained with **Ac-FluNox** and analyzed by nFCM. Analysis of liposome size distribution following refractive index correction using Mie theory revealed that variations in encapsulated  $\text{Fe}^{2+}$  concentration had negligible effects on particle size distribution (Fig. S3 and S4). The observed heterogeneity in size and fluorescence distributions reflects the size-dependent loading variability inherent to liposome

populations (Fig. 2a(ii)). Both the percentage ratio and median FL intensity of  $\text{Fe}^{2+}$ -positive-liposomes ( $\text{Fe}^{2+}$ -LPs) showed concentration-dependent responses to  $\text{Fe}^{2+}$  (Fig. 2c and d). The strong linear correlation ( $R^2 = 0.9812$ ) between  $\text{Fe}^{2+}$ -LPs' median FL intensity and  $\text{Fe}^{2+}$  loading concentration demonstrates **Ac-FluNox**'s capability for quantifying  $\text{Fe}^{2+}$  in single particles *via* nFCM (Fig. 2d). These results establish the nFCM-based single-particle  $\text{Fe}^{2+}$  detection method as a robust platform for intravesicular  $\text{Fe}^{2+}$  analysis with direct applicability to EV studies.

### Property characterization of EVs derived from ferroptotic cells


The nFCM-based single-particle  $\text{Fe}^{2+}$  detection method was applied to analyze EVs derived from HT-1080 cells, a well-established human fibrosarcoma cell line for ferroptosis research. EVs were isolated through sequential centrifugation (1000g, 5 min; 2000g, 10 min) and ultracentrifugation (100 000g, 2 h, twice) (Fig. 3a). TEM imaging confirmed typical EV morphology (Fig. 3b and S5), while Western blotting verified the presence of classical EV markers CD9 and TSG101 and the absence of the endoplasmic reticulum (ER) marker calnexin in the EV preparation (Fig. 3c). Triton X-100 treatment, developed in our previous study,<sup>31,36</sup> was conducted, affirming a purity (defined as the detergent sensitivity) of 88.6% for the HT-1080 EVs isolate (Fig. 3d).

Three ferroptosis inducers were used to treat HT-1080 cells: ammonium ferric citrate (FAC, 0–200  $\mu\text{g mL}^{-1}$ ), RSL3 (0–2  $\mu\text{M}$ ), and erastin (0–4  $\mu\text{M}$ ). FAC serves as a direct iron source that elevates intracellular labile iron pool (LIP) levels through cellular uptake and subsequent reduction.<sup>2,37</sup> Both RSL3 and erastin are classical ferroptosis inducers that indirectly increase intracellular  $\text{Fe}^{2+}$  levels through promoting ferritin degradation, RSL3 through GPX4 inhibition and erastin *via* system  $x_c^-$  blockade.<sup>1</sup> All treatments (48 h incubation) maintained >80% cell viability (Fig. S6). Iron



**Fig. 2** Analysis of  $\text{Fe}^{2+}$  in individual  $\text{Fe}^{2+}$ -encapsulated liposomes using nFCM. (a) Schematic diagram of liposome formulations with graded  $\text{Fe}^{2+}$  concentrations (0–4.0  $\mu\text{M}$ ) (i) and representative bivariate dot-plots of  $\text{Fe}^{2+}$  fluorescence (FL) *versus* particle size for liposomes labeled with **Ac-FluNox** (ii). (b) Microfluidic device schematic for liposomes synthesis. (c) Scatter plot presenting percentage ratios of  $\text{Fe}^{2+}$ -LPs. (d) Linear regression correlating FL median with intra-liposomal  $\text{Fe}^{2+}$  concentration. Initial concentration of liposome:  $\sim 5.0 \times 10^{10}$  particles per mL. The concentrations of  $\text{Fe}^{2+}$ -LPs were calculated by multiplying the positive ratios with the initial liposome concentration. Error bars represent standard deviation (s.d.) of three replicate experiments ( $n = 3$ , mean  $\pm$  s.d.).





**Fig. 3** Characterization of EVs released during ferroptosis. (a) Workflow of EV isolation and purification from HT-1080 cells. (b) Representative TEM micrograph of EVs isolated from the conditioned cell culture medium (CCM) of untreated HT-1080 cells. (c) Immunoblots comparing a cell lysate with an EV preparation (10 µg protein per lane). (d) Side scatter (SSC) distribution histograms of EVs before and after Triton X-100 treatment. (e) Quantitative comparison of secreted particle concentration of EVs under different treatment conditions in per mL of conditioned medium. (f) Comparison of EV size distribution under different treatment conditions. Error bars represent the standard deviation (s.d.) of three replicate experiments ( $n = 3$ , mean  $\pm$  s.d.).

overload conditions significantly enhanced EV secretion (Fig. 3e), suggesting a stress-responsive regulatory mechanism in parental cells. Notably, all EV populations exhibited similar size distributions (Fig. 3f), confirming the preservation of EV integrity under different iron metabolic states. Taken together, the isolated EVs met all quality criteria for subsequent Fe<sup>2+</sup> profiling.

### Single-particle analysis of Fe<sup>2+</sup> in EVs during ferroptosis via nFCM

Previous studies have established the association between Fe<sup>2+</sup> fluctuations and ferroptosis, with distinct cellular Fe<sup>2+</sup> levels observed across different induction pathways.<sup>1</sup> However, whether ferroptosis drives Fe<sup>2+</sup> accumulation in



**Fig. 4** Analysis of Fe<sup>2+</sup> in EVs derived from ferroptotic HT-1080 cells treated with different ferroptosis inducers. (a) Schematic diagram of the regulatory mechanisms of FAC, RSL3, and erastin on iron metabolism. (b) Fe<sup>2+</sup> level in HT-1080 cells treated with different inducers by flow cytometric analysis. (c) Confocal microscope images of Ac-FluNox-stained HT-1080 cells treated with different inducers. (d) Bivariate dot-plots of FL versus particle size of EVs derived from different treatments. (e) Absolute concentrations of Fe<sup>2+</sup>-positive EVs calculated by multiplying the positive ratios from panel (d) with corresponding total particle concentrations. (f) Bar graphs presenting FL median of Fe<sup>2+</sup> positive EVs in (d). The labels i-iv represent different treatments (i: control, ii: 200 µg mL<sup>-1</sup> FAC, iii: 2.0 µM RSL3, and iv: 2.0 µM erastin). Scale bar: 20 µm. The error bar represents the standard deviation (s.d.) of three replicate experiments ( $n = 3$ , mean  $\pm$  s.d.).



EVs, and whether EVs serves as an iron export mechanism parallel to ferroportin FPN, remains unclear. Capitalizing on the single-particle resolution of nFCM for intravesicular  $\text{Fe}^{2+}$  analysis, we performed quantitative mapping of  $\text{Fe}^{2+}$  in individual EVs. Initial investigations focused on FAC-induced iron overload (Fig. 4a). Flow cytometry and confocal microscopy confirmed dose-dependent intracellular  $\text{Fe}^{2+}$  accumulation in HT-1080 cells after 48-hour FAC treatment (Fig. 4b and c and S7). To compare the correlation between parental cells and EVs in  $\text{Fe}^{2+}$  content, **Ac-FluNox** was used to label  $\text{Fe}^{2+}$  in EVs. nFCM analysis revealed FAC concentration-dependent increases in  $\text{Fe}^{2+}$ -positive EV ratios and their median fluorescence intensity, which were attenuated by the iron chelator deferoxamine (DFO), confirming the iron-dependent nature of these responses (Fig. S8). These results, combined with the FAC-induced increase in EV secretion

(Fig. 3e) demonstrate synchronized intracellular–extracellular  $\text{Fe}^{2+}$  dynamics, suggesting a regulatory link between cellular iron status and EV biogenesis.

We extended these observations to ferroptosis inducers that indirectly alter iron homeostasis through promoting ferritin degradation (Fig. 4a). Flow cytometry and fluorescence microscopy imaging (Fig. 4b and c) demonstrated RSL3- and erastin-induced iron overload in HT-1080 cells, mediated by ferritin degradation followed by  $\text{Fe}^{3+}$  release and reduction. EVs generated under ferroptosis induction exhibited  $\text{Fe}^{2+}$  accumulation patterns similar to those of FAC-treated EVs (Fig. 4b–f and S8), with increases in both particle concentration and median fluorescence intensity of  $\text{Fe}^{2+}$ -positive populations. Together, these results demonstrate that iron-overloaded cells actively release  $\text{Fe}^{2+}$ -enriched EVs, with their  $\text{Fe}^{2+}$  content closely linked to



**Fig. 5** Analysis of  $\text{Fe}^{2+}$  in EVs derived from ferroptotic HT-1080 cells under FPN inhibition. (a and b) Flow cytometric analysis (a) and confocal microscope images (b) of intracellular  $\text{Fe}^{2+}$  level in HT-1080 cells treated with different conditions upon **Ac-FluNox** staining. (c) Bivariate dot-plots of FL versus particle size of  $\text{Fe}^{2+}$ -EVs derived from different treatments. (d and e) Bar graphs of the particle concentration (d) and FL median intensity (e) of  $\text{Fe}^{2+}$ -EVs in (c). Scale bar: 20  $\mu\text{m}$ . (f) Schematic diagram of the dual-phase iron export systems. The labels i–iii represent different treatments (i: control, ii: 1.0  $\mu\text{M}$  VIT-2763, and iii: 1.0  $\mu\text{M}$  VIT-2763 + 200  $\mu\text{g}/\text{mL}$  FAC). The error bar represents the standard deviation (s.d.) of three replicate experiments ( $n = 3$ , mean  $\pm$  s.d.).



parental cell iron metabolism—supporting the involvement of an active transport process.

### Exploring the relationship between FPN and EVs in Fe<sup>2+</sup> export

Building on nFCM evidence of EV-mediated iron homeostasis regulation during stress (Fig. 4b–f and S8), we postulated that EVs might functionally compensate for FPN deficiency by providing an alternative Fe<sup>2+</sup> efflux pathway. To test this, we employed VIT-2763, a specific FPN inhibitor, to pharmacologically block canonical iron efflux.<sup>38</sup> Consistent with FPN inhibition, quantitative analysis revealed significant intracellular Fe<sup>2+</sup> accumulation in HT-1080 cells (Fig. 5a and b), while parallel detection of EV-associated Fe<sup>2+</sup> confirmed compensatory extracellular export (Fig. 5c–e). Notably, under combined FPN inhibition and iron overload induced by FAC, RSL3, or erastin, elevated particle concentrations and Fe<sup>2+</sup> FL intensities of Fe<sup>2+</sup>-EVs were observed (Fig. 5c–e, S9 and S10). These results further demonstrate that EV-mediated Fe<sup>2+</sup> export increases proportionally with both pharmacological FPN inhibition and pathological iron overload. Collectively, these findings establish a dual-phase iron export system wherein iron-overloaded cells not only export Fe<sup>2+</sup> *via* FPN but also release Fe<sup>2+</sup> into the extracellular microenvironment in an EV-dependent manner. Importantly, EV-mediated efflux is further activated as an adaptive response to FPN dysfunction (Fig. 5f schematic). This spontaneous compensatory mechanism likely represents a cellular safeguard against iron toxicity when FPN-mediated export pathway is compromised.

## Conclusions

In conclusion, this study elucidates the regulatory role of EVs in iron homeostasis, with specific focus on Fe<sup>2+</sup>. By developing a novel analytical platform combining Fe<sup>2+</sup>-specific fluorescent chemosensor (**Ac-FluNox**) with nFCM, we achieved single-EV resolution for quantitative Fe<sup>2+</sup> characterization. This approach enabled the precise characterization of Fe<sup>2+</sup> distribution and content in EVs, revealing a strong correlation between Fe<sup>2+</sup> levels in EVs and their parental cells. Moreover, we discovered the capacity of EVs to function as an auxiliary Fe<sup>2+</sup> export system complementing FPN-mediated efflux. This study not only advances the understanding of iron regulatory networks by demonstrating EV-mediated Fe<sup>2+</sup> transport but also establishes a versatile platform for investigating the heterogeneity and functional significance of EVs in iron metabolism and associated pathological conditions. While the current methodology specifically detects free Fe<sup>2+</sup>, future studies incorporating nFCM's multiparametric capabilities could extend to iron-containing cargos (*e.g.*, ferritin), offering more comprehensive insights into EV-mediated iron communication. This direction would further unravel the multifaceted roles of EVs in iron regulation under physiological and pathological conditions.

## Conflicts of interest

The authors declare the following competing financial interest(s): X. Y. declares competing financial interest as a cofounder of NanoFCM Inc., a company committed to commercializing the nano-flow cytometry (nFCM) technology.

## Data availability

Supplementary information is available: Including experimental details and supplementary results. See DOI: <https://doi.org/10.1039/D5SD00060B>.

The data supporting this article have been included as part of the SI.

## Acknowledgements

We thank the National Key R&D Program of China (2021YFA0909400 and 2024YFA1108700) the National Natural Science Foundation of China (32450337 and 21934004) for the support.

## References

- 1 S. J. Dixon and J. A. Olzmann, *Nat. Rev. Mol. Cell Biol.*, 2024, **25**, 424–442.
- 2 B. Galy, M. Conrad and M. Muckenthaler, *Nat. Rev. Mol. Cell Biol.*, 2024, **25**, 133–155.
- 3 K. B. Muchowska, S. J. Varma and J. Moran, *Nature*, 2019, **569**, 104–107.
- 4 M. W. Hentze, M. U. Muckenthaler, B. Galy and C. Camaschella, *Cell*, 2010, **142**, 24–38.
- 5 P. Matak, A. Matak, S. Moustafa, D. K. Aryal, E. J. Benner, W. Wetsel and N. C. Andrews, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, 3428–3435.
- 6 F. X. Sun, Z. Z. Zhao, M. M. Willoughby, S. Q. Shen, Y. Zhou, Y. Y. Shao, J. Kang, Y. T. Chen, M. Y. Chen, X. J. Yuan, I. Hamza, A. R. Reddi and C. Y. Chen, *Nature*, 2022, **610**, 768–774.
- 7 K. Kawai, T. Hirayama, H. Imai, T. Murakami, M. Inden, I. Hozumi and H. Nagasawa, *J. Am. Chem. Soc.*, 2022, **144**, 3793–3803.
- 8 R. C. Hider and X. L. Kong, *BioMetals*, 2011, **24**, 1179–1187.
- 9 S. J. Patel, A. G. Frey, D. J. Palenchar, S. Achar, K. Z. Bullough, A. Vashisht, J. A. Wohlschlegel and C. C. Philpott, *Nat. Chem. Biol.*, 2019, **15**, 872–881.
- 10 L. C. Montemiglio, C. Testi, P. Ceci, E. Falvo, M. Pitea, C. Savino, A. Arcovito, G. Peruzzi, P. Baiocco, F. Mancina, A. Boffi, A. d. Georges and B. Vallone, *Nat. Commun.*, 2019, **10**, 1121.
- 11 J. Gruszczyk, U. Kanjee, L. J. Chan, S. Menant, B. Malleret, N. T. Y. Lim, C. Q. Schmidt, Y. F. Mok, K. M. Lin, R. D. Pearson, G. Rangel, B. J. Smith, M. J. Call, M. P. Weekes, M. D. W. Griffin, J. M. Murphy, J. Abraham, K. Sriprawat, M. J. Menezes, M. U. Ferreira, B. Russell, L. Renia, M. T. Duraisingh and W. H. Tham, *Science*, 2018, **359**, 48–55.
- 12 H. H. Jabara, S. E. Boyden, J. Chou, N. Ramesh, M. J. Massaad, H. Benson, W. Bainter, D. Fraulino, F. Rahimov, C.



- Sieff, Z. J. Liu, S. H. Alshemmari, B. K. Al-Ramadi, H. Al-Dhekri, R. Arnaout, M. Abu-Shukair, A. Vatsayan, E. Silver, S. Ahuja, E. G. Davies, M. Sola-Visner, T. K. Ohsumi, N. C. Andrews, L. D. Notarangelo, M. D. Fleming, W. Al-Herz, L. M. Kunkel and R. S. Geha, *Nat. Genet.*, 2016, **48**, 74–78.
- 13 I. Yanatori, D. R. Richardson, H. S. Dhekne, S. Toyokuni and F. Kishi, *Blood*, 2021, **138**, 1490–1503.
- 14 C. W. Brown, J. J. Amante, P. Chhoy, A. L. Elaimy, H. Liu, L. J. Zhu, C. E. Baer, S. J. Dixon and A. M. Mercurio, *Dev. Cell*, 2019, **51**, 575–586.
- 15 M. Truman-Rosentsvit, D. Berenbaum, L. Spektor, L. A. Cohen, S. Belizowsky-Moshe, L. Lifshitz, J. Ma, W. Li, E. Kesselman, I. Abutbul-Ionita, D. Danino, L. Gutierrez, H. H. Li, K. Y. Li, H. F. Lou, M. Regoni, M. Poli, F. Glaser, T. A. Rouault and E. G. Meyron-Holtz, *Blood*, 2018, **131**, 342–352.
- 16 R. Kalluri and V. S. LeBleu, *Science*, 2020, **367**, 640.
- 17 M. Tkach and C. Théry, *Cell*, 2016, **164**, 1226–1232.
- 18 G. van Niel, G. D'Angelo and G. Raposo, *Nat. Rev. Mol. Cell Biol.*, 2018, **19**, 213–228.
- 19 G. S. Bi, J. Q. Liang, Y. Y. Bian, G. Y. Shan, Y. W. Huang, T. Lu, H. Zhang, X. Jin, Z. C. Chen, M. N. Zhao, H. Fan, Q. Wang, B. Y. Gan and C. Zhan, *Nat. Commun.*, 2024, **15**, 2461.
- 20 C. W. Brown and A. M. Mercurio, *Mol. Cell. Oncol.*, 2020, **7**, e1730144.
- 21 H. K. C. Co, C. C. Wu, Y. C. Lee and S. H. Chen, *Nature*, 2024, **631**, 654–662.
- 22 A. Purnianto, C. Mawal, M. M. Kulkarni, H. Su, T. F. Koukoulis, P. Wongsodirdjo, Y. H. Hung, S. Ayton, A. I. Bush, K. J. Barnham and L. J. Vella, *J. Extracell. Biol.*, 2024, **3**, e70012.
- 23 C. Alarcón-Veleiro, R. Mato-Basalo, S. Lucio-Gallego, A. Vidal-Pampín, M. Quindós-Varela, T. Al-Qatarnah, G. Berrecoso, A. Vizoso-Vázquez, M. C. Arufe and J. Fafián-Labora, *Antioxidants*, 2023, **12**, 183.
- 24 K. Grover, A. Koblova, A. T. Pezacki, C. J. Chang and E. J. New, *Chem. Rev.*, 2024, **124**, 5846–5929.
- 25 K. Lee, K. Fraser, B. Ghaddar, K. Yang, E. Kim, L. Balaj, E. A. Chiocca, X. O. Breakefield, H. Lee and R. Weissleder, *ACS Nano*, 2018, **12**, 494–503.
- 26 Y. N. Guo, J. Tao, Y. R. Li, Y. M. Feng, H. X. Ju, Z. F. Wang and L. Ding, *J. Am. Chem. Soc.*, 2020, **142**, 7404–7412.
- 27 J. L. Zhang, J. J. Shi, H. L. Zhang, Y. F. Zhu, W. Liu, K. X. Zhang and Z. Z. Zhang, *J. Extracell. Vesicles*, 2020, **10**, e12025.
- 28 B. Q. Lin, T. Tian, Y. Z. Lu, D. Liu, M. J. Huang, L. Zhu, Z. Zhu, Y. L. Song and C. Y. Yang, *Angew. Chem., Int. Ed.*, 2021, **60**, 7582–7586.
- 29 H. S. Liu, Y. Tian, C. F. Xue, Q. Niu, C. Chen and X. M. Yan, *J. Extracell. Vesicles*, 2022, **11**, e12206.
- 30 S. B. Zhu, L. Ma, S. Wang, C. X. Chen, W. Q. Zhang, L. L. Yang, W. Hang, J. P. Nolan, L. N. Wu and X. M. Yan, *ACS Nano*, 2014, **8**, 10998–11006.
- 31 Y. Tian, L. Ma, M. F. Gong, G. Q. Su, S. B. Zhu, W. Q. Zhang, S. Wang, Z. B. Li, C. X. Chen, L. H. Li, L. N. Wu and X. M. Yan, *ACS Nano*, 2018, **12**, 671–680.
- 32 T. Peng and D. Yang, *Org. Lett.*, 2010, **12**, 496–499.
- 33 T. Hirayama, H. Tsuboi, M. Niwa, A. Miki, S. Kadota, Y. Ikeshita, K. Okuda and H. Nagasawa, *Chem. Sci.*, 2017, **8**, 4858–4866.
- 34 G. Adamo, S. Picciotto, P. Gargano, A. Paterna, S. Raccosta, E. Rao, D. P. Romancino, G. Ghersi, M. Manno, M. Salamone and A. Bongiovanni, *J. Extracell. Vesicles*, 2025, **14**, e70030.
- 35 K. Wardhani, A. Levina, G. E. R. Grau and P. A. Lay, *Chem. Soc. Rev.*, 2024, **53**, 6779–6829.
- 36 N. G. Cai, X. Z. Zhan, Y. Chen, J. W. Xue, C. Chen, Y. R. Li, Y. Tian and X. M. Yan, *Anal. Chem.*, 2024, **96**, 12718–12728.
- 37 J. A. Pan, W. Y. Xiong, A. L. Zhang, H. Zhang, H. Lin, L. Gao, J. H. Ke, S. Y. Huang, J. F. Zhang, J. Gu, A. C. Y. Chang and C. Q. Wang, *Adv. Sci.*, 2023, **10**, 2206007.
- 38 V. Manolova, N. Nyffenegger, A. Flace, P. Altermatt, A. Varol, C. Doucerain, H. Sundstrom and F. Dürrenberger, *J. Clin. Invest.*, 2020, **130**, 491–506.

